A breakthrough clinical trial in gene editing by RheumaGen is revolutionizing the treatment of autoimmune disorders. RG0401 targets specific HLA alleles to encode molecules found in individuals resistant to rheumatoid arthritis. By extracting a patient’s hematopoietic stem cells (HSCs) and introducing engineered HLA alleles ex vivo, the therapy aims to create cells with modified HLA molecules that prevent autoimmune responses. This innovative approach disrupts the autoimmune cascade by producing antigen-presenting cells incapable of triggering an immune response, effectively halting the disease at its source. The potential impact of this precision medicine technique is promising, offering hope for those suffering from autoimmune conditions. Stay informed about the latest developments in clinical trials for gene editing and the future of personalized cell therapy.
Read more about this — here
